(Reuters) - Biotechnology company Sarepta Therapeutics Inc said U.S. health regulators granted fast track status to two of its experimental drugs for the treatment of the Marburg and Ebola viruses. Shares of the company rose 7 percent to $15.95 on Tuesday morning on the Nasdaq. A fast track designation by the U.S. Food and Drug Administration expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs. Data from clinical trials for such drugs can be submitted to the FDA on a rolling basis rather than waiting until pivotal studies are completed. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment